News und Analysen
![Sensationeller Erfolg im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 206% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 206% mit Biotech Hot Stock: https://www.irw-press.at/prcom/images/messages/2023/71323/AC-130723-2.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOVpNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--de98086908f29e9baed0751938cefe6b077f7f63/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-130723-2.001.png?locale=de)
Sensationeller Erfolg im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 206% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 206% mit Biotech Hot Stock
Sensationeller Erfolg im Kampf gegen Hautkrebs - Massives Kaufsignal. 206% Biotech Aktientip nach 134.452% mit Biogen
13.07.23 08:18
London (www.aktiencheck.de, Anzeige)
![Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71305/Aktiencheck_Vidac_120723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenRMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5b3f64bfef07fa8bd92ce1bf962296d13aace5ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck_Vidac_120723.001.png?locale=de)
Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Erstkl. Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. 208% Biotech Hot Stock nach 31.205% mit Amgen
12.07.23 08:02
London (www.aktiencheck.de, Anzeige)
![Accolade: A Rising Personalized AI-Powered Healthcare Platform: https://www.marketbeat.com/logos/articles/med_20230709131618_chart-accd.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0pKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--81a0aaf652672922732493576c882991a89eb45f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230709131618_chart-accd.jpg?locale=de)
Accolade: A Rising Personalized AI-Powered Healthcare Platform
Accolade Inc. (NASDAQ: ACCD) is an artificial intelligence (AI) powered healthcare platform that provides personalized healthcare guidance for employers and workers. The platform helps people
![Biotech Hot Stock erzielt Durchbruch im Kampf gegen Hautkrebs. Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 208% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Bi: https://www.irw-press.at/prcom/images/messages/2023/71290/Aktiencheck110723_01.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNDlKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--787d8ebddd6748c6adbc693ec025f1daf5be4277/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck110723_01.001.png?locale=de)
Biotech Hot Stock erzielt Durchbruch im Kampf gegen Hautkrebs. Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 208% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Bi
Biotech Hot Stock erzielt Durchbruch im Kampf gegen Hautkrebs - Massives Kaufsignal. 208% Biotech Aktientip nach 134452%
11.07.23
London (www.aktiencheck.de, Anzeige)
![3 Stocks that Analysts Continue to Upgrade into Earnings Season: https://www.marketbeat.com/logos/articles/med_20230710103919_3-stocks-that-analysts-continue-to-upgrade-into-ea.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0JJYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6d48418cdefa572eb5dc3539f217fd530805a7a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230710103919_3-stocks-that-analysts-continue-to-upgrade-into-ea.jpg?locale=de)
3 Stocks that Analysts Continue to Upgrade into Earnings Season
One simple signal that investors can use to decide if a stock is likely to move higher is to look at analyst sentiment. An analyst is a market professional employed by either funds that buy
![Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi: https://www.marketbeat.com/logos/articles/med_20230707134150_biogen-shares-fall-after-fda-approval-of-alzheimer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmRJYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1dbde6a5e8e414c90db91c96080cd62ebf404107/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230707134150_biogen-shares-fall-after-fda-approval-of-alzheimer.jpg?locale=de)
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Stocks often react differently from the way you think they might. That happened on July 7 as shares of Biogen Inc. (NASDAQ: BIIB) swooned 2.88% in heavy trading volume following news of full
![Hautkrebs bald besiegt? Round Table mit Europas Top-Forschern. Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 210% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Bi: https://www.irw-press.at/prcom/images/messages/2023/71270/AC-100723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzlJYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a7bf8398bb6a9cb8511ab94d21b47a578fbf7566/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-100723.001.png?locale=de)
Hautkrebs bald besiegt? Round Table mit Europas Top-Forschern. Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 210% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Bi
Hautkrebs bald besiegt? Round Table mit Europas Top-Forschern. 210% Biotech Aktientip nach 15.973% mit BioNTech ($BNTX)
10.07.23 08:11
London (www.aktiencheck.de, Anzeige)
![Pfizer Just Invested $25 million In This Biotech: https://www.marketbeat.com/logos/articles/med_20230707085820_pfizer-just-invested-25-million-in-this-biotech.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeGxIYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--262be44f890d0485b2cae73bedbf5cf6c7ecbcc9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230707085820_pfizer-just-invested-25-million-in-this-biotech.jpg?locale=de)
Pfizer Just Invested $25 million In This Biotech
Shares of Caribou Biosciences (NASDAQ: CRBU) were up 45% yesterday after Pfizer (NYSE: PFE) made a $25 million equity investment. On Thursday, the company said Pfizer bought almost 4.7 million
![Hautkrebs bald besiegt? Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 212% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 212% mit Biotech Ak: https://www.irw-press.at/prcom/images/messages/2023/71257/AC-070723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNHBHYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0d3a54f1f977c1100e4201991eea788b0e347107/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-070723.001.png?locale=de)
Hautkrebs bald besiegt? Erstklassige Studienergebnisse. Massives Kaufsignal. Neuer 212% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 212% mit Biotech Ak
Hautkrebs bald besiegt? Erstkl. Studienergebnisse. Massives Kaufsignal. 212% Biotech Hot Stock nach 134.452% mit Biogen
07.07.23 08:02
London (www.aktiencheck.de, Anzeige)
![Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy: https://www.marketbeat.com/logos/articles/med_20230706072115_inspire-medical-up-15-after-breakout-analysts-say.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEZGYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d93c1e48be6f980dcbdddeaf24104c58d261befa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230706072115_inspire-medical-up-15-after-breakout-analysts-say.jpg?locale=de)
Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy
Inspire Medical Systems (NYSE: INSP) is up nearly 15% since breaking out of cup-with-handle base on May 3. The base’s buy point was above $277.18, which you can see on the Inspire Medical Systems
![Eilt: Durchbruch im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 217% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vida: https://www.irw-press.at/prcom/images/messages/2023/71245/AC-060723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeE5GYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--56515343a35b8591b959e4c64524c8811c3d4a26/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-060723.001.png?locale=de)
Eilt: Durchbruch im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 217% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vida
Eilt: Durchbruch im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 217% Biotech Aktientip nach 15.973% mit BioNTech
06.07.23 08:02
London (www.aktiencheck.de , Anzeige)
![Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac : https://www.irw-press.at/prcom/images/messages/2023/71224/AC_VidacPharma_050723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzVEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e681713d74d225c9ff5e1cb9ac83ef3ff82c2797/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC_VidacPharma_050723.001.png?locale=de)
Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac
Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 134.452% mit Biogen
05.07.23 08:17
London (www.aktiencheck.de, Anzeige)
![Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71203/Acresearch040723_01.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1pEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9cf6ff849545ee031a7c43df64ea5ff8aadf9f90/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Acresearch040723_01.001.png?locale=de)
Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 31.205% mit Amgen ($AMGN)
04.07.23
London (www.aktiencheck.de, Anzeige)
![Freyr Battery Powers Up After Successful Tests, NYSE Presentation: https://www.marketbeat.com/logos/articles/med_20230630155856_freyr-battery-powers-up-after-successful-tests-nys.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL1pDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3248ddfcf206970b1822acf9617e69869e31d484/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230630155856_freyr-battery-powers-up-after-successful-tests-nys.png?locale=de)
Freyr Battery Powers Up After Successful Tests, NYSE Presentation
Investors dream of getting into a promising stock early before it goes on a rocket ride. In hindsight, plenty of investors are kicking themselves for not seeing the potential of Apple Inc.
![Krebs bald besiegt? Sensationelle Studienergebnisse. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 224% mit Biotech Aktientip Vidac Pharma : https://www.irw-press.at/prcom/images/messages/2023/71194/AC-030723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHhDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--411a50a5bdc2c7746cdb91e78cd09754c59906ac/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-030723.001.png?locale=de)
Krebs bald besiegt? Sensationelle Studienergebnisse. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 224% mit Biotech Aktientip Vidac Pharma
Krebs bald besiegt? Sensationelle Studienergebnisse. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX)
03.07.23 08:17
London (www.aktiencheck.de , Anzeige)
![Down Over 80%, is Pet Insurer Trupanion Worth the Risk Premium?: https://www.marketbeat.com/logos/articles/med_20230628085658_down-over-80-is-pet-insurer-trupanion-worth-the-ri.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeGcvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4be8624fb66483f59315b7139989339d80c40dd2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230628085658_down-over-80-is-pet-insurer-trupanion-worth-the-ri.jpg?locale=de)
Down Over 80%, is Pet Insurer Trupanion Worth the Risk Premium?
As shareholders of pet insurer Trupanion Inc. (NASDAQ: TRUP) learned last month, when you post a net loss that's twice what Wall Street expected, things get a little fuzzy.
The May 5
![MoonLake Immunotherapeutics Makes a Moonshot on Trials: https://www.marketbeat.com/logos/articles/med_20230627135359_chart-mltx.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0ErYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1cc03209bfa7ceffd01997226b0d66c205cde5a1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230627135359_chart-mltx.jpg?locale=de)
MoonLake Immunotherapeutics Makes a Moonshot on Trials
Clinical stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive phase two clinical trial results. The company specializes in nanobodies, fragments of antibodies
![Drugmaker GSK: Becoming a Healthier Value Stock: https://www.marketbeat.com/logos/articles/med_20230627104026_drugmaker-gsk-is-becoming-a-healthier-value-stock.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNk05YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7bbe39798ab222547de5cee9d4543eeb3e06110a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230627104026_drugmaker-gsk-is-becoming-a-healthier-value-stock.jpg?locale=de)
Drugmaker GSK: Becoming a Healthier Value Stock
Like most stocks during the dot-com bubble, GSK PLC (NYSE: GSK) partied like it was 1999. In the two decades since, missteps and competitive pressures slashed roughly 50% from the U.K. pharmaceuti
![PetVivo Sales Spryng Higher on Injectable OA Relief for Pets: https://www.marketbeat.com/logos/articles/med_20230625124449_chart-petv.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2s5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--efdca3e4c81165944c72af47405b33464700a014/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230625124449_chart-petv.jpg?locale=de)
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets
Developmental biomedical device company PetVivo Holdings Inc. (OTCMKTS: PETV) makes pet medical devices and therapeutics. What kind of medical devices would pets need? Pacemakers? Artificial hearts
![Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?): https://www.marketbeat.com/logos/articles/med_20230627075714_sarepta-therapeutics-gets-fda-nod-drops-warning-or.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2c5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--11d7fc716d18f31038739ea2f4ae949de71f293c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230627075714_sarepta-therapeutics-gets-fda-nod-drops-warning-or.jpg?locale=de)
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)
On May 15, Sarepta Therapeutics Inc. (NASDAQ: SRPT) learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA)
![ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials: https://www.marketbeat.com/logos/articles/med_20230625130240_chart-imgn2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFU3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f735c6464d2acbda7d33d652f24106d39bfad031/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230625130240_chart-imgn2.jpg?locale=de)
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver
![Patterson Companies Leverages Healthcare For Income Investors: https://www.marketbeat.com/logos/articles/med_20230621111455_chart-pdco-6212023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNHM0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9e565820e12e1ae1a1dc3e75fbb2372445983c12/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230621111455_chart-pdco-6212023.png?locale=de)
Patterson Companies Leverages Healthcare For Income Investors
Patterson Companies, Inc. (NASDAQ: PDCO) is a dual-story that includes healthcare for humans and animals. The company operates in 2 segments, Dental and Animal Health, and both are growing. The
![T-Mobile Stock's Decline: Does Value Potential Exist?: https://www.marketbeat.com/logos/articles/med_20230621142449_t-mobile-stocks-decline-does-value-potential-exist.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBem80YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--edc6b6fd1210a9dfb664c493152c07f960ab5c18/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230621142449_t-mobile-stocks-decline-does-value-potential-exist.jpg?locale=de)
T-Mobile Stock's Decline: Does Value Potential Exist?
Investors rarely get to consider a blue-chip company like T-Mobile US (NASDAQ: TMUS) amid a decline of more than 17% during the past two months. As the underlying stock carries a beta of only
![Agilent Technologies Stock: Ready to Rise off the Floor: https://www.marketbeat.com/logos/articles/med_20230618154044_chart-a.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMVkzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--188a72726abf10a7aac6282ab60da0fd63c1cbf5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230618154044_chart-a.jpg?locale=de)
Agilent Technologies Stock: Ready to Rise off the Floor
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down 19% year-to-date. Agilent is a leading global provider of laboratory technologies and equipment.
It counts
![DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth: https://www.marketbeat.com/logos/articles/med_20230621092054_dexcom-clears-base-wall-street-eyes-double-digit-e.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemszYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d3d87051d76f3ae81f566cb4ca52b727c1a31e16/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230621092054_dexcom-clears-base-wall-street-eyes-double-digit-e.jpg?locale=de)
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
You generally associate Super Bowl commercials with products made by PepsiCo Inc. (NYSE: PEP) or the Coca-Cola Co. (NYSE: KO), but earlier this year, glucose-monitoring geat maker DexCom Inc.